Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?
| Autor: | Fishman J; From the NYU Langone, New York, NY., Buchbinder EI; Dana-Farber Cancer Institute, Boston, MA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer journal (Sudbury, Mass.) [Cancer J] 2024 Mar-Apr 01; Vol. 30 (2), pp. 120-125. |
| DOI: | 10.1097/PPO.0000000000000703 |
| Abstrakt: | Abstract: Immune checkpoint inhibition and targeted therapies have revolutionized the treatment of melanoma. However, chemotherapy and interleukin 2 (IL-2) therapy may still have a role in the later-line treatment of patients who do not have durable responses to other treatments. Chemotherapy can work transiently in patients whose disease has progressed on immune checkpoint inhibitors and for whom there are no appropriate targeted therapy options. High-dose IL-2 therapy can still be effective for a very small number of patients following progression on other therapies. In addition, modified IL-2 agents and IL-2 in combination with tumor-infiltrating lymphocyte therapy may play a role in future treatments for melanoma. Competing Interests: Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|